Condition: Prurigo Nodularis · Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
This description comes directly from the study's public registry record.
xiaofeng xiao Cai, bachelor · 02151371305 · xiaofeng.cai@mabgeek.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital, Beijing, | Beijing, Bejing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06779136